Sung H,Ferlay J,Siegel RL,Laversanne M,Soerjomataram I,Jemal A,Cancer J Clin A .2021 .GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Global Cancer Statistics, 10(3) : 209-249.
Zheng RS,Zhang SW,Zeng HM,Wang S,Sun K,Chenet R,Nat Cancer Center J .2022 .Cancer incidence and. , 02(1) : 1-9.
Chen Y,Chen Y,Wang Z,Li H,Wang Y. .2022 .Clinical value of propranolol combined with oxaliplatin and tigio in concurrent chemoradiotherapy for locally advanced gastric cancer. Pak J Med Sci, 10(5) : 5311-1320.
Li WW,Jiao J,Wang ZY,Wei YN,Zhang YF. .2021 .Clinical efficacy of immunotherapy combined with chemotherapy in patients with advanced gastric cancer, its effect on nutritional status and Changes of peripheral blood T lymphocyte subsets. Pak J Med Sci, 10(7) : 4347-1907.
Bouzid R,Peppelenbosch M,Buschow SI .2020 .Opportunities for Conventional and in Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review. Cancers (Basel), 10(5) : 1121.
Janjigian YY,Kawazoe A,Bai Y,Xu J,Lonardi S,Metges JP .2023 .Pembrolizumab plus trastuzumab and chemotherapy for HER2- positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet, 6736(23) : 02033-0.
Shitara K,Ajani JA,Moehler M,Garrido M,Gallardo C,Shen L .2022 .Nivolumab plus chemotherapy or ipilimumab in gastrooesophageal cancer. Nature, 10(7903) : 942-948.
Kwon HJ,Park MI,Park SJ,Moon W,Kim SE,Kim JH .2019 .Insulin Resistance Is Associated with Early Gastric Cancer: A Prospective Multicenter Case Control Study. Gut Liver, 10(2) : 154-160.
Shitara K,Bang YJ,Iwasa S,Sugimoto N,Ryu MH,Sakai D .2020 .Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med, 10(25) : 2419-2430.
Zhou N,Zhang C,Liu D,Liu K,Wang G,Zhu H .2021 .Apatinib in Combination with S-1 as First-Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single-Arm, Phase II Trial. , 10(3) : e374-e381.
Wei J,Lu X,Liu Q,Li L,Liu S,Liu F .2020 .. Case Report: Neoadjuvant PD-1 Blockade Plus Concurrent Chemoradiotherapy in Unresectable Locally Advanced Gastric Cancer Patients. Front Oncol, 10 : 554040.
Zhang Y,Wang F,Sun HR,Huang YK,Gao JP,Huang H .2021 .Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer. J Cancer Res Clin Oncol, 10(8) : 2209-2222.
Zhang L,Wang W,Ge S,Li H,Bai M,Duan J .2023 .Sintilimab Plus Apatinib and Chemotherapy as Second/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial. BMC Cancer, 10(1) : 211.
Roviello G,Ravelli A,Polom K,Petrioli R,Marano L,Marrelli D .2016 .Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett, 01(2) : 187-191.
Luo Q,Dong Z,Xie W,Fu X,Lin L,Zeng Q .2023 .Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy. Cell Rep, 10(5) : 112437.
Lin R,Fan N,Li H,Liu J,Zhao S,Yu J .2020 .Apatinib reverses resistance of paclitaxel-containing regimens in advanced gastric cancer: A phase II study. , 10(Suppl 9) : ix53-ix54.
Zheng Y,Yang X,Yan C,Feng R,Sah BK,Yang Z .2020 .Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial. Eur J Cancer, 02 : 12-19.
Wang Y,Zhao J,Yu H,Wang J,Zhang N,Cao B .2021 .Efficacy and safety of sintilimab-based regimens against advanced gastric and gastroesophageal junction adenocarcinoma. J Cancer Res Ther, 856(5) : 21-1240.
Jiang H,Yu X,Li N,Kong M,Zhou Z,D Z .2022 .Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study. -003635, 10(3) : .